Skip to main content
. Author manuscript; available in PMC: 2018 Dec 12.
Published in final edited form as: Leukemia. 2018 Jun 5;32(12):2536–2545. doi: 10.1038/s41375-018-0147-4

Figure 2.

Figure 2

Kaplan-Meyer curves depicting overall survival of patients with de novo AML according to the presence or absence of NF1 mutations. (a) Patients <60 years of age belonging to the ELN 2017 adverse risk group with any NF1 mutation (red) compared with patients without NF1 mutations (blue). (b) Patients <60 years of age with NF1 Thr676 mutations (red) compared with patients without these mutations (blue).